Overview of Course
The purpose of this activity is to provide the learner with knowledge and practice of evidence-based neuromuscular monitoring and pharmacological reversal of neuromuscular blockade.
Upon completion of this course, the learner will be able to:
1. Define residual neuromuscular blockade and list its major complications.
2. Describe current practice and limitations of neuromuscular blockade monitoring and reversal.
3. Describe objective monitoring of neuromuscular blockade.
4. Discuss the pharmacology of sugammadex and its advantages over traditional neuromuscular blockade reversal agents.
5. List considerations for reducing rates of residual neuromuscular blockade in the absence of objective monitoring measures, based on current evidence.
Verification of Participation
The participant will have only 2 opportunities to successfully complete the course post-test, which is comprised of 10 random questions pulled from the test pool of questions. The passing score of at least 80% is required for the exam in this course. If the participant fails the post test, he or she will not receive CE credits for this course.
This course has been prior approved by the AANA for 1.0 Class A CE credit; AANA Code Number: 1036164.
The AANA designates this program as meeting the criteria for up to 1.0 CE Credit in Pharmacology/Therapeutics.
Course Expiration Date: 4/12/2021
The American Association of Nurse Anesthetists is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
AANA is an approved provider by the California Board of Registered Nursing, CEP #10862.